BC-005 is under clinical development by Dragonboat Biopharmaceutical (Shanghai) and currently in Phase I for Asthma. According to GlobalData, Phase I drugs for Asthma have a 73% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how BC-005’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

BC-005 overview

BC-005 is under development for the treatment of asthma. The drug candidate is a monoclonal antibody that acts by targeting interleukin 4 receptor (IL-4R).

Dragonboat Biopharmaceutical (Shanghai) overview

Dragonboat Biopharmaceutical (Shanghai) (Dragonboat Biopharmaceutical) is the research and development laboratory of Dragonfly Sciences, the US. It discovers and develops antibody therapeutics. Its platforms includes Analysis and Evaluation Platform, Process Development Platform, GMP Manufacturing Platform, Discovery platform, Quality Management Platform and Regulatory Affairs Platform. It discovers, develops, and commercializes genetically engineered human proteins for therapeutic use. Based on its proprietary protein expression technology, the company produces Erythropoietin, a drug that treats severe anemia. Dragonboat Biopharmaceutical is headquartered in Shanghai, China.

For a complete picture of BC-005’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.